FIELD: chemistry.
SUBSTANCE: group of inventions relates to organic chemistry and includes 1,5-benzothiazepine derivatives of formula (I), individual compounds specified in the claim, pharmaceutically acceptable salts thereof, a pharmaceutical composition based thereon and use thereof. In formula (I), R1 and R2 are each independently C1-4alkyl; R3 is independently selected from a group consisting of hydrogen, halogen, hydroxy, C1-4alkyl, C1-4haloalkyl, C1-4alkoxy, C1-4haloalkoxy, cyano, nitro, amino, N-(C1-4alkyl) amino, N,N-di(C1-4alkyl)amino and N-(aryl-C1-4alkyl)amino; n is equal to integer 1, 2 or 3; R4 is selected from a group consisting of C3-6cycloalkyl, C3-6cycloalkyloxy and C3-6cycloalkylthio.
EFFECT: compounds of formula (I), having an apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transporter (LBAT) inhibition activity.
13 cl, 8 tbl, 20 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BENZOTHIA(DI)AZEPINE COMPOUNDS AND USE THEREOF AS BILE ACID MODULATORS | 2021 |
|
RU2841263C1 |
| BENZOTHIA (DI) AZEPINE COMPOUNDS AND USE THEREOF AS BILE ACID MODULATORS | 2020 |
|
RU2838220C1 |
| BENZOTHIA(DI)AZEPINE COMPOUNDS AND USE THEREOF AS BILE ACID MODULATORS | 2020 |
|
RU2827704C1 |
| BENZOTHIAZEPINE COMPOUNDS AND USE THEREOF AS BILE ACID MODULATORS | 2020 |
|
RU2817535C2 |
| BENZOTHIADIAZEPINE COMPOUNDS AND USE THEREOF AS BILE ACID MODULATORS | 2020 |
|
RU2838136C1 |
| BENZOTHIA(DI)AZEPINES AND THEIR USE AS BILE ACID MODULATORS | 2019 |
|
RU2785867C2 |
| BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACIDS MODULATORS | 2020 |
|
RU2814570C2 |
| N1/N2-LACTAM ACETYL-CoA-CARBOXYLASE INHIBITORS | 2011 |
|
RU2540337C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING PEPTIDE VERSIONS, AND METHODS OF USING THEM | 2015 |
|
RU2729161C2 |
| COMPOSITION FOR TREATING IGF-1R EXPRESSING CANCER | 2016 |
|
RU2728568C2 |
